ATE178214T1 - System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe - Google Patents

System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe

Info

Publication number
ATE178214T1
ATE178214T1 AT92903020T AT92903020T ATE178214T1 AT E178214 T1 ATE178214 T1 AT E178214T1 AT 92903020 T AT92903020 T AT 92903020T AT 92903020 T AT92903020 T AT 92903020T AT E178214 T1 ATE178214 T1 AT E178214T1
Authority
AT
Austria
Prior art keywords
active substances
diagnostic
improved
extracorporeal removal
target
Prior art date
Application number
AT92903020T
Other languages
English (en)
Inventor
Rune Nilsson
Lars Lindgren
Kristina Norrgren
Bengt Sandberg
Hans-Olof Sjoegren
Sven-Erik Strand
Original Assignee
Rune Nilsson
Lars Lindgren
Kristina Norrgren
Bengt Sandberg
Sjoegren Hans Olof
Strand Sven Erik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rune Nilsson, Lars Lindgren, Kristina Norrgren, Bengt Sandberg, Sjoegren Hans Olof, Strand Sven Erik filed Critical Rune Nilsson
Application granted granted Critical
Publication of ATE178214T1 publication Critical patent/ATE178214T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92903020T 1991-01-17 1992-01-15 System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe ATE178214T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9100142A SE9100142L (sv) 1991-01-17 1991-01-17 En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal

Publications (1)

Publication Number Publication Date
ATE178214T1 true ATE178214T1 (de) 1999-04-15

Family

ID=20381639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92903020T ATE178214T1 (de) 1991-01-17 1992-01-15 System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe

Country Status (10)

Country Link
US (2) US6251394B1 (de)
EP (1) EP0567514B1 (de)
JP (1) JP3471352B2 (de)
AT (1) ATE178214T1 (de)
CA (1) CA2100256C (de)
DE (1) DE69228802T2 (de)
DK (1) DK0567514T3 (de)
ES (1) ES2130167T3 (de)
SE (1) SE9100142L (de)
WO (1) WO1992012730A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
CA2178477A1 (en) * 1993-12-07 1995-06-15 Louis J. Theodore Pretargeting methods and compounds
AU2191795A (en) * 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
JP2000503301A (ja) * 1996-01-11 2000-03-21 テクニクローン インコーポレーティッド 減少した正味の正電荷を有する抗体
US8951499B2 (en) 1996-02-08 2015-02-10 University Of Washington Trifunctional reagent for conjugation to a biomolecule
EP1049499B1 (de) * 1998-01-20 2003-10-15 Mitra Medical Technology AB Apparat zur verwendung bei der entfernung von elementen, insbesondere antikörpern aus blut und plasma
US6533734B1 (en) * 1999-06-11 2003-03-18 The Board Of Trustees Of The University Of Illinois Time-integrated sampler of bodily fluid
IT1310933B1 (it) * 1999-11-16 2002-02-27 Luigi Benatti Macchina multifunzionale per il monitoraggio ed il controllo diterapie locoregionali in oncologia.
MXPA02012438A (es) * 2000-06-16 2004-09-06 Dept Of Radiation Oncology Uni Columnas extracorporeas para uso repetido, cargadas con conjugados de ligando-dibiotina.
SE0002287D0 (sv) * 2000-06-16 2000-06-16 Department Of Radiation Oncolo Biotinderivat
EP1420641A4 (de) * 2001-08-01 2005-05-25 Anil K Chauhan Immunkomplexe
US20050271653A1 (en) * 2002-04-23 2005-12-08 Meir Strahilevitz Methods and devices for targeting a site in a mammal and for removing species from a mammal
US20040044300A1 (en) * 2002-09-03 2004-03-04 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
US20040077985A1 (en) * 2002-09-03 2004-04-22 Donnie Rudd Method of replenishing cells damaged by treatment for cancer
WO2004071446A2 (en) * 2003-02-12 2004-08-26 Chauhan Anil K Immune complexes
US20060193839A1 (en) * 2005-02-28 2006-08-31 Donnie Rudd Method of providing readily available cellular material derived from peripheral blood, and a composition thereof
US20080075704A1 (en) * 2005-02-28 2008-03-27 Wolf David A Method of providing readily available cellular material derived from peripheral blood, and a composition thereof
US20110014151A1 (en) * 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
WO2012142180A1 (en) * 2011-04-12 2012-10-18 Tianxin Wang Methods to detect and treat diseases
US9549953B2 (en) * 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
EP2814514B1 (de) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US4371515A (en) 1978-12-26 1983-02-01 E-Y Laboratories, Inc. Method for forming an isolated lectin-immunological conjugate
US4223672A (en) 1979-02-08 1980-09-23 Baxter Travenol Laboratories, Inc. Variable volume plasma treatment chamber for an apparatus for the extracorporeal treatment of disease
US4215688A (en) 1979-02-09 1980-08-05 Baxter Travenol Laboratories, Inc. Apparatus for the extracorporeal treatment of disease
US4350156A (en) 1980-05-29 1982-09-21 Japan Foundation For Artificial Organs Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid
US4824432A (en) 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4687808A (en) 1982-08-12 1987-08-18 Biospecific Technologies, Inc. Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors
CA1221307A (en) 1982-12-02 1987-05-05 Nobutaka Tani Adsorbent and process for preparing the same
CA1236738A (en) 1983-06-01 1988-05-17 Mark R. Honard Therapeutic device
US4551435A (en) 1983-08-24 1985-11-05 Immunicon, Inc. Selective removal of immunospecifically recognizable substances from solution
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4877599A (en) 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5122112A (en) * 1986-11-21 1992-06-16 Imre Corporation Antigen-specific removal of circulating immune complexes
US4800016A (en) 1986-11-24 1989-01-24 The University Of Michigan Extracorporeal blood de-heparinization system
DE3705637A1 (de) * 1987-02-21 1988-09-29 Bissendorf Peptide Gmbh Vorrichtung zur entfernung von lokal applizierten wirkstoffen gegen solide tumoren
US4846786A (en) 1987-04-30 1989-07-11 Massachusetts Institute Of Technology Bioreactor containing suspended, immobilized species
US4885207A (en) * 1987-07-13 1989-12-05 Uop Biocompatible protein or ligand immobilization system
US4865841A (en) 1987-10-23 1989-09-12 Imre Corporation Methods and compositions for transient elimination of humoral immune antibodies
US5069662A (en) * 1988-10-21 1991-12-03 Delcath Systems, Inc. Cancer treatment
US5149425A (en) 1988-11-09 1992-09-22 Chembiomed, Ltd. Affinity supports for hemoperfusion
CA2025899A1 (en) 1989-01-23 1990-07-24 Reinhard Bredehorst Site specific in-vivo activation of therapeutic drugs
US5252466A (en) * 1989-05-19 1993-10-12 Biotechnology Research And Development Corporation Fusion proteins having a site for in vivo post-translation modification and methods of making and purifying them
EP0436717B1 (de) * 1989-08-02 2003-02-26 Mitra Medical Technology AB System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
US5474772A (en) * 1989-08-02 1995-12-12 Cobe Laboratories, Inc. Method of treatment with medical agents
WO2000002050A1 (en) 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule

Also Published As

Publication number Publication date
DE69228802D1 (de) 1999-05-06
EP0567514A1 (de) 1993-11-03
JPH06504542A (ja) 1994-05-26
CA2100256C (en) 2004-06-08
JP3471352B2 (ja) 2003-12-02
US6723318B1 (en) 2004-04-20
WO1992012730A1 (en) 1992-08-06
DE69228802T2 (de) 1999-10-14
CA2100256A1 (en) 1992-07-18
DK0567514T3 (da) 1999-10-18
EP0567514B1 (de) 1999-03-31
SE9100142L (sv) 1992-07-18
SE9100142D0 (sv) 1991-01-17
ES2130167T3 (es) 1999-07-01
US6251394B1 (en) 2001-06-26

Similar Documents

Publication Publication Date Title
DE69228802D1 (de) System zur verbesserten in-vivo aussonderung diagnostischer und/oder therapeutischer wirkstoffe durch extrakorporales entfernen der wirkstoffe
DE3580973D1 (de) Geraet zur bestrahlung von blutteilen.
EP0364799A3 (en) Cancer treatment
DK0436717T3 (da) System til anvendelse ved en fremgangsmåde til terapeutisk eller diagnostisk behandling
ATE28571T1 (de) Schlauchsystem zur behandlung von blut ausserhalb des koerpers and aehnlichen leichtverderblichen fluessigkeiten.
Stone et al. Mobilization of Radioactive Sodium from the Gastrocnemius Muscle of the Dog.
ATE150323T1 (de) Vorrichtung zur extrakorporalen trennung von fluorchemikalien
Ng New approaches to treatment of chronic pain: a review of multidisciplinary pain clinics and pain centers
ATE65413T1 (de) Geraet zur aussenkoerperlichen behandlung von koerperlichen fluessigkeiten.
ITFI20020208A1 (it) Apparecchiatura utilizzabile in trattamenti di emofiltrazione.
Gourlay et al. The effect of haemodilution on blood/biomaterial contact-mediated CD11b expression on neutrophils: ex vivo studies
Oliveira et al. Experimental model for removal of snake venom via hemoperfusion in rats
ATE86498T1 (de) Verminderung des gehaltes an lipoproteine mit geringer dichte in biologischen fluessigkeiten.
Duwe et al. Regulation of DNA synthesis and antibody production by soluble factors released by bone marrow cells
Kyogoku et al. Clinical and basic studies on the G-1 column, a new extracorporeal therapeutic device effective in controlling rheumatoid arthritis
Lipman et al. Role of dialysable solutes in the mediation of uremic encephalopathy in the rat
CH658391A5 (de) Verfahren zur herstellung von humanem gamma-interferon.
Lewis et al. Severe haemoptysis associated with viral tracheitis
SU942757A1 (ru) Способ лечени хронического тонзиллита
DE102004010695B4 (de) Vorrichtung zur Reinigung von Blut
SU1015895A1 (ru) Способ очистки крови
Biggs The treatment of haemophilia
RU2195322C2 (ru) Способ лечения и профилактики печеночной недостаточности путем детоксикации крови
UA10842C2 (uk) Спосіб лікуваhhя хроhічhого та хроhічhого рецидивуючого паhкреатитів
CA2037933A1 (en) Method of Treatment with Medical Agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee